Find information on thousands of medical conditions and prescription drugs.


Giardiasis (also known as beaver fever) is a disease caused by the flagellate protozoan Giardia lamblia (also Giardia intestinalis). The giardia organism inhabits the digestinal tract of a wide variety of domestic and wild animal species as well as humans. It is a common cause of gastroenteritis in humans, infecting approximately 200 million people worldwide. more...

Gardner's syndrome
Gastric Dumping Syndrome
Gastroesophageal reflux
Gaucher Disease
Gaucher's disease
Gelineau disease
Genu varum
Geographic tongue
Gerstmann syndrome
Gestational trophoblastic...
Giant axonal neuropathy
Giant cell arteritis
Gilbert's syndrome
Gilles de la Tourette's...
Gitelman syndrome
Glanzmann thrombasthenia
Glioblastoma multiforme
Glucose 6 phosphate...
Glycogen storage disease
Glycogen storage disease...
Glycogen storage disease...
Glycogenosis type IV
Goldenhar syndrome
Goodpasture's syndrome
Graft versus host disease
Graves' disease
Great vessels transposition
Growth hormone deficiency
Guillain-Barré syndrome

Giardiasis is passed via the fecal-oral route. Primary routes are personal contact and contaminated water and food. People who spend time in institutional or day-care environments are more susceptible, as are travelers and those who consume improperly treated water. It is a particular danger to people hiking or backpacking in wilderness areas worldwide. It is zoonotic -- communicable between animals and humans. Major reservoir hosts include beavers, dogs, cats, horses, and cattle.

Symptoms include loss of appetite, lethargy, diarrhea, loose or watery stool, stomach cramps, upset stomach, bloating and flatulence. Symptoms typically begin 1-2 weeks after infection and may wane and reappear cyclically. Symptoms are caused largely by the thick coating of Giardia organisms coating the inside of the small intestine and blocking nutrient absorption. Most people are asymptomatic; only about a third of infected people exhibit symptoms.

Antibiotics used to treat adults include metronidazole, albenzazole and quinacrine. Furazolidone and nitazoxanide may be used in children. Treatment is not always necessary, as the body can defeat the infection by itself.

Outside North America the drug Tinidazole trade name Fagisyn or Tindamax can treat Giardiasis in a single treatment of 2,000 mg. instead of the longer treatment of the other medications listed, with less distress due to the shorter treatment duration.


[List your site here Free!]

Diagnosis, treatment and prevention of giardiasis - Tips from Other Journals
From American Family Physician, 2/15/98 by Jeffrey T. Kirchner

Giardiasis has become an increasingly common cause of diarrhea and malabsorption in humans. Thirty-four outbreaks of giardiasis were reported in the United States from 1993 to 1994, compared with just six outbreaks in 1984. Ortega and Adam review the epidemiology and life cycle of Giardia and discuss current treatment and prevention.

Giardia lamblia is most often transmitted through contaminated water or food, or by the fecal-oral route. Outbreaks peak in late summer, except in day care centers, where no seasonal patterns have been observed. G. lamblia occurs throughout the world and is most prevalent in areas with poor water treatment or unsanitary conditions. The seroprevalence in developing countries ranges from 20 to 30 percent. Most of these persons are asymptomatic. A seroprevalence rate as high as 35 percent has been reported in children attending day care centers. Although many of these children are asymptomatic, they may transmit the infection to family members.

The usual incubation period for symptomatic giardiasis is one to two weeks but may vary from one to 45 days. However, as many as 60 percent of persons exposed to the infection remain asymptomatic. Patients who develop symptoms usually have loose diarrhea with foul-smelling, non-bloody stools. Other common symptoms include flatulence, abdominal cramps, bloating, anorexia, nausea and weight loss. Fever sometimes occurs at the onset of infection. Malabsorption is common and is the likely cause of the substantial weight loss that may occur. Unlike those with other forms of infectious diarrhea, patients with giardiasis will usually be symptomatic for one to two weeks before seeking medical attention. The illness may resolve spontaneously, but symptoms may persist for weeks and sometimes for months. Chronic infection occurs despite the presence of an antibody-mediated immune response. The reasons for this are unclear; however, the antibodies do seem to provide protection against newly acquired infection or reinfection.

The diagnosis of giardiasis is usually confirmed by the presence of cysts or, less frequently, trophozoites in stool specimens stained with trichome or iron hematoxylin. The sensitivity of this test can be improved by repeating the stool examination on one or two additional specimens. Giardia antigens can be detected in stool specimens using monoclonal antibodies or direct fluorescent assays. These tests should be considered if the results of routine stool examinations are nondiagnostic. Serodiagnosis is not useful because current antibody tests are unable to differentiate between present and prior infection.

In patients with persistent symptoms, a string test may be useful. In this test, the patient swallows a capsule on the end of a string which migrates to the jejunum, where the trophozoites attach. The string is withdrawn after four hours or more and can then be examined for trophozoites. Some clinicians prefer to proceed to esophagogastroduodenoscopy with duodenal aspiration and biopsy. This method aids in the detection of other diseases that may cause similar symptoms, such as lymphoma, Whipple's disease, cryptosporidiosis, isosporiasis or Crohn's disease.

Several effective treatments are currently available for patients with symptomatic giardiasis (see the accompanying table). The majority of patients will respond to a five-day course of metronidazole. Quinacrine hydrochloride had been considered the drug of choice for giardiasis but, due to the side effects of hemolysis and toxic psychosis in some patients with glucose-6 phosphate dehydrogenase deficiency, it is no longer commercially available in the United States. Tinidazole, given as a single dose, is widely used throughout the world but is not labeled for this use by the U.S. Food and Drug Administration. Furazolidone is currently the only drug labeled for the treatment of giardiasis in the United States and is often used to treat children. Albendazole seems to be comparable to metronidazole in efficacy and has fewer side effects. Paromomycin is a nonabsorbable aminoglycoside that is not as effective as the other available agents but is commonly used for the treatment of giardiasis in pregnant women.

COPYRIGHT 1998 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group

Return to Giardiasis
Home Contact Resources Exchange Links ebay